10 Healthcare Ideas on My Watchlist Right Now
A collection of companies I find interesting enough to track closely, but haven’t yet taken through the full deep-dive process.
To read our full disclaimer, click here.
This is The Clinical Edge Watchlist - a collection of companies I find interesting enough to track closely, but haven’t yet taken through the full deep-dive process. Some of these may graduate to full thesis posts. Some may not. A few might end up in the portfolio. Others might fall off the list entirely as I learn more.
Think of this as a window into my research pipeline.
Let’s get into it.
kneat.com (TSX: KSI)
Kneat digitizes validation and quality processes for life sciences companies - replacing the paper and Excel workflows that pharmaceutical manufacturers still use to meet regulatory standards. They've landed most of the top 20 global pharma companies and follow a land-and-expand model, starting at one site and growing across an organization's global footprint. Strong gross margins, improving leverage, and a regulatory moat that makes adoption increasingly inevitable. On my watchlist because the TAM remains underpenetrated and the valuation could get interesting if expansion into adjacent verticals gains traction.
Spok Holdings (NASDAQ: SPOK)
Spok is the dominant provider of communication solutions to the healthcare market, best known for wireless paging services used by clinicians and first responders. While the legacy paging business is in steady decline, an activist-driven turnaround has refocused the company on cost discipline, software growth, and capital returns. The result is a business now generating meaningful free cash flow, paying a large dividend, and buying back stock - all while trading below a previously rejected takeover bid. On my watchlist because the downside feels well-protected by the capital return story, with optionality if the software pivot gains traction or M&A interest resurfaces.
High Tide Inc. (TSXV: HITI)
High Tide is Canada's largest cannabis retailer, operating a discount club model anchored by the world's largest cannabis loyalty program. Think Costco for cannabis - membership-driven, scale-advantaged procurement, and a price leadership strategy that continues to take share in a maturing market. The company is founder-led, profitable, and expanding internationally with early moves into Germany and ambitions for US entry as regulations evolve. On my watchlist because the unit economics of the membership model create a widening moat, and if even a fraction of the international optionality plays out, today's valuation could look cheap.
The Full Watchlist
The three names above are just the beginning. Below, I’m sharing the remaining seven companies on my radar - spanning Japanese healthcare tech, clinical-stage biotech, respiratory care, pain management, surgical hospitals, and more.
Each one has a different flavour of asymmetry. Some are classic value setups with free cash flow and buybacks. Others are binary bets on regulatory outcomes. A few are compounders hiding in plain sight.